Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upifitamab rilsodotin + carboplatin in ovarian cancer
NCT04907968Phase 1Terminated
- Sponsor
- Mersana Therapeutics
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of upifitamab rilsodotin in High-Grade Serous Ovarian Carcinoma (HGSOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Mersana Therapeutics. Primary endpoints: Maximum Tolerated Dose up to 24 weeks and Feasibility of Combination. Started Jun 2021; status: terminated.
02
Drugs
upifitamab rilsodotin
03
Conditions
High-Grade Serous Ovarian Carcinoma (HGSOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04907968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04907968.